PlainRecalls
FDA Drug Critical Class I Terminated

Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY 10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL 61103, NDC 67457-467-99.

Reported: August 19, 2015 Initiated: March 18, 2015 #D-1328-2015

Product Description

Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY 10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL 61103, NDC 67457-467-99.

Reason for Recall

Presence of Particulate Matter

Details

Recalling Firm
Mylan Institutional LLC
Units Affected
a) 15,095 vials b) 300 vials
Distribution
Nationwide and Puerto Rico
Location
Rockford, IL

Frequently Asked Questions

What product was recalled?
Methotrexate Injection, USP 50 mg/2 mL (25 mg/mL), 2 mL Single-dose Vial, packaged in 5 x 2 mL vials per carton, Rx only, labeled as a) Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY 10017, NDC 0069-0146-01; and b) Manufactured for: Mylan Institutional LLC, Rockford, IL 61103, NDC 67457-467-99.. Recalled by Mylan Institutional LLC. Units affected: a) 15,095 vials b) 300 vials.
Why was this product recalled?
Presence of Particulate Matter
Which agency issued this recall?
This recall was issued by the FDA Drug on August 19, 2015. Severity: Critical. Recall number: D-1328-2015.